These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 23138940)
1. Growth kinetics of CD133-positive prostate cancer cells. Reyes EE; Kunovac SK; Duggan R; Kregel S; Vander Griend DJ Prostate; 2013 May; 73(7):724-33. PubMed ID: 23138940 [TBL] [Abstract][Full Text] [Related]
2. In vitro identification and characterization of CD133(pos) cancer stem-like cells in anaplastic thyroid carcinoma cell lines. Zito G; Richiusa P; Bommarito A; Carissimi E; Russo L; Coppola A; Zerilli M; Rodolico V; Criscimanna A; Amato M; Pizzolanti G; Galluzzo A; Giordano C PLoS One; 2008; 3(10):e3544. PubMed ID: 18958156 [TBL] [Abstract][Full Text] [Related]
3. Human α(2)β(1)(HI) CD133(+VE) epithelial prostate stem cells express low levels of active androgen receptor. Williamson SC; Hepburn AC; Wilson L; Coffey K; Ryan-Munden CA; Pal D; Leung HY; Robson CN; Heer R PLoS One; 2012; 7(11):e48944. PubMed ID: 23145034 [TBL] [Abstract][Full Text] [Related]
4. The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Vander Griend DJ; Karthaus WL; Dalrymple S; Meeker A; DeMarzo AM; Isaacs JT Cancer Res; 2008 Dec; 68(23):9703-11. PubMed ID: 19047148 [TBL] [Abstract][Full Text] [Related]
5. The identification of a novel antibody for CD133 using human antibody phage display. Glumac PM; Forster CL; Zhou H; Murugan P; Gupta S; LeBeau AM Prostate; 2018 Sep; 78(13):981-991. PubMed ID: 29790189 [TBL] [Abstract][Full Text] [Related]
6. Regulation of the stem cell marker CD133 is independent of promoter hypermethylation in human epithelial differentiation and cancer. Pellacani D; Packer RJ; Frame FM; Oldridge EE; Berry PA; Labarthe MC; Stower MJ; Simms MS; Collins AT; Maitland NJ Mol Cancer; 2011 Jul; 10():94. PubMed ID: 21801380 [TBL] [Abstract][Full Text] [Related]
7. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Miki J; Furusato B; Li H; Gu Y; Takahashi H; Egawa S; Sesterhenn IA; McLeod DG; Srivastava S; Rhim JS Cancer Res; 2007 Apr; 67(7):3153-61. PubMed ID: 17409422 [TBL] [Abstract][Full Text] [Related]
8. Isolation, characterization and mobilization of prostate cancer tissue derived CD133+ MDR1+ cells. Rentala S; Mangamoori LN J Stem Cells; 2010; 5(2):75-81. PubMed ID: 22049617 [TBL] [Abstract][Full Text] [Related]
9. CD49f is an efficient marker of monolayer- and spheroid colony-forming cells of the benign and malignant human prostate. Yamamoto H; Masters JR; Dasgupta P; Chandra A; Popert R; Freeman A; Ahmed A PLoS One; 2012; 7(10):e46979. PubMed ID: 23071686 [TBL] [Abstract][Full Text] [Related]
10. Cancer stem-like cells in human prostate carcinoma cells DU145: the seeds of the cell line? Wei C; Guomin W; Yujun L; Ruizhe Q Cancer Biol Ther; 2007 May; 6(5):763-8. PubMed ID: 17592251 [TBL] [Abstract][Full Text] [Related]
11. CD133 (Prominin) negative human neural stem cells are clonogenic and tripotent. Sun Y; Kong W; Falk A; Hu J; Zhou L; Pollard S; Smith A PLoS One; 2009; 4(5):e5498. PubMed ID: 19430532 [TBL] [Abstract][Full Text] [Related]
12. Expression analysis of putative stem cell markers in human benign and malignant prostate. Ugolkov AV; Eisengart LJ; Luan C; Yang XJ Prostate; 2011 Jan; 71(1):18-25. PubMed ID: 20583131 [TBL] [Abstract][Full Text] [Related]
13. Side population rather than CD133(+) cells distinguishes enriched tumorigenicity in hTERT-immortalized primary prostate cancer cells. Zhou J; Wang H; Cannon V; Wolcott KM; Song H; Yates C Mol Cancer; 2011 Sep; 10():112. PubMed ID: 21917149 [TBL] [Abstract][Full Text] [Related]
14. Human epithelial basal cells are cells of origin of prostate cancer, independent of CD133 status. Taylor RA; Toivanen R; Frydenberg M; Pedersen J; Harewood L; ; Collins AT; Maitland NJ; Risbridger GP Stem Cells; 2012 Jun; 30(6):1087-96. PubMed ID: 22593016 [TBL] [Abstract][Full Text] [Related]
15. Glucose transporter-1 expression in CD133+ laryngeal carcinoma Hep-2 cells. Chen XH; Bao YY; Zhou SH; Wang QY; Wei Y; Fan J Mol Med Rep; 2013 Dec; 8(6):1695-700. PubMed ID: 24146103 [TBL] [Abstract][Full Text] [Related]
16. In vivo investigation of CD133 as a putative marker of cancer stem cells in Hep-2 cell line. Wei XD; Zhou L; Cheng L; Tian J; Jiang JJ; Maccallum J Head Neck; 2009 Jan; 31(1):94-101. PubMed ID: 18853445 [TBL] [Abstract][Full Text] [Related]
17. Description of the CD133+ subpopulation of the human ovarian cancer cell line OVCAR3. Guo R; Wu Q; Liu F; Wang Y Oncol Rep; 2011 Jan; 25(1):141-6. PubMed ID: 21109969 [TBL] [Abstract][Full Text] [Related]
18. Expression profiling of CD133+ and CD133- epithelial cells from human prostate. Shepherd CJ; Rizzo S; Ledaki I; Davies M; Brewer D; Attard G; de Bono J; Hudson DL Prostate; 2008 Jun; 68(9):1007-24. PubMed ID: 18398820 [TBL] [Abstract][Full Text] [Related]
19. CD133(+)CXCR4(+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients. Zhang SS; Han ZP; Jing YY; Tao SF; Li TJ; Wang H; Wang Y; Li R; Yang Y; Zhao X; Xu XD; Yu ED; Rui YC; Liu HJ; Zhang L; Wei LX BMC Med; 2012 Aug; 10():85. PubMed ID: 22871210 [TBL] [Abstract][Full Text] [Related]
20. Effect of CD133/prominin-1 antisense oligodeoxynucleotide on in vitro growth characteristics of Huh-7 human hepatocarcinoma cells and U251 human glioma cells. Yao J; Zhang T; Ren J; Yu M; Wu G Oncol Rep; 2009 Oct; 22(4):781-7. PubMed ID: 19724856 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]